Literature DB >> 2809757

Characterization of technetium-99m-L,L-ECD for brain perfusion imaging, Part 2: Biodistribution and brain imaging in humans.

J Léveillé1, G Demonceau, M De Roo, P Rigo, R Taillefer, R A Morgan, D Kupranick, R C Walovitch.   

Abstract

The safety, biodistribution and kinetics of a new perfusion imaging agent [99mTc-L,L]-ethyl cysteinate dimer (ECD) was evaluated in normal volunteers. Technetium-99m-L,L-ECD is a neutral, lipophilic complex, which is radiochemically pure and stable. Twelve healthy adults were injected with 25-30 mCi of 99mTc-L,L-ECD and imaged periodically for up to 24 hr. Planar imaging showed rapid brain uptake with a peak concentration of 4.9% injected dose and very slow brain washout (approximately 6% per hour during the first 6 hr). Repeat or dynamic tomographic imaging of the brain using either a rotating gamma camera or a multidetector system was performed up to 6 hr postinjection. The distribution of 99mTc-L,L-ECD in the brain did not change and was similar to the pattern seen with other perfusion agents. Background facial areas and lungs cleared rapidly. Peak blood activity was below 10% injected dose at all times and 99mTc-L,L-ECD cleared rapidly through the kidneys. Vital signs, blood and urine chemistries were normal in all volunteers and no adverse reactions were noted. These results suggest that 99mTc-L,L-ECD should be useful for routine assessment of cerebral perfusion in humans.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2809757

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  20 in total

Review 1.  Single-photon emission computed tomography in neurotherapeutics.

Authors:  Michael D Devous
Journal:  NeuroRx       Date:  2005-04

Review 2.  Radiopharmaceuticals: state of the art.

Authors:  A M Verbruggen
Journal:  Eur J Nucl Med       Date:  1990

Review 3.  A brief overview of metal complexes as nuclear imaging agents.

Authors:  Douglas S MacPherson; Kimberly Fung; Brendon E Cook; Lynn C Francesconi; Brian M Zeglis
Journal:  Dalton Trans       Date:  2019-10-07       Impact factor: 4.390

Review 4.  Brain imaging during seizure: ictal brain SPECT.

Authors:  S R Kottamasu
Journal:  Indian J Pediatr       Date:  1997 Sep-Oct       Impact factor: 1.967

5.  Cerebral blood flow and autoregulation: current measurement techniques and prospects for noninvasive optical methods.

Authors:  Sergio Fantini; Angelo Sassaroli; Kristen T Tgavalekos; Joshua Kornbluth
Journal:  Neurophotonics       Date:  2016-06-21       Impact factor: 3.593

6.  Abnormal regional cerebral blood flow on 99mTc ECD brain SPECT in patients with primary Sjögren's syndrome and normal findings on brain magnetic resonance imaging.

Authors:  C P Chang; Y C Shiau; J J Wang; S T Ho; A Kao
Journal:  Ann Rheum Dis       Date:  2002-09       Impact factor: 19.103

7.  Non-matched images with 123I-IMP and 99mTc-bicisate single-photon emission tomography in the demonstration of focal hyperaemia during the subacute phase of an ischaemic stroke.

Authors:  F Tamgac; J L Moretti; G Defer; P Weinmann; A Roussi; P Cesaro
Journal:  Eur J Nucl Med       Date:  1994-03

8.  Quantitative comparison between 99mTc-HMPAO and 99mTc-ECD: measurement of arterial input and brain retention.

Authors:  A Pupi; A Castagnoli; M T De Cristofaro; L Bacciottini; A R Petti
Journal:  Eur J Nucl Med       Date:  1994-02

9.  Usefulness of Tc-99m ECD brain SPECT to evaluate the effects of methylprednisolone pulse therapy in lupus erythematosus with brain involvement: a preliminary report.

Authors:  F Y Liu; W S Huang; C H Kao; R F Yen; J J Wang; S T Ho
Journal:  Rheumatol Int       Date:  2003-01-30       Impact factor: 2.631

10.  Detecting abnormal regional cerebral blood flow in patients with primary Sjögren's syndrome by technetium-99m ethyl cysteinate dimer single photon emission computed tomography of the brain--a preliminary report.

Authors:  W S Huang; P Y Chiu; A Kao; C H Tsai; C C Lee
Journal:  Rheumatol Int       Date:  2003-02-18       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.